Why should you buy Vedanta shares despite strong Hindustan Zinc Q2 results 2026? Experts' views, target price

What happened: Hindustan Zinc reported Q2 results with EBITDA of ₹9,290 crore, up 14.20% QoQ, beating market estimates. Analysts at Systematix Institutional Equities and Emkay Global Financial Services maintained buy ratings on Hindustan Zinc and Vedanta shares. Key numbers: Q2 EBITDA ₹9,290 crore, up 14.20% QoQ; revenue ₹14,582 crore, up 76% YoY Why it matters: Emkay expects Vedanta to benefit from Hindustan Zinc's strong results given its 90% EBITDA contribution. Systematix raised FY27E/FY28E EBITDA estimates by 23%/9% and sees 26% upside on Hindustan Zinc from the current market price. Coverage: 3 outlets in 24h

Hindustan Zinc reported Q2 results with EBITDA of ₹9,290 crore, up 14.20% QoQ, beating market estimates. Analysts at Systematix Institutional Equities and Emkay Global Financial Services maintained buy ratings on Hindustan Zinc and Vedanta shares.

Emkay expects Vedanta to benefit from Hindustan Zinc's strong results given its 90% EBITDA contribution. Systematix raised FY27E/FY28E EBITDA estimates by 23%/9% and sees 26% upside on Hindustan Zinc from the current market price.